Rare neurodevelopmental abnormalities of sarcosinemia may involve glycinergic stimulation of a primed N-methyl-d-aspartate receptor

Clinical Neuropharmacology

Volumn 29, Issue 6, 2006, Pages 361-363

  Deutsch, Stephen I ^a,b   Rosse, Richard B ^a,b   Long, Katrice D ^a   Gaskins, Brooke ^a   Mastropaolo, John ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glycine; NMDA receptor; Sarcosinemia

Indexed keywords

CARBON; DIZOCILPINE; GLYCINE RECEPTOR; GLYCINE TRANSPORTER 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; SARCOSINE;

AMINO ACID BLOOD LEVEL; AMINO ACID URINE LEVEL; AUTOSOMAL RECESSIVE DISORDER; BRAIN DEVELOPMENT; BRAIN MALFORMATION; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DYSPHORIA; EXPERIMENTAL STUDY; FETUS OUTCOME; HALLUCINATION; HEREDITY; HUMAN; METABOLISM; MOOD DISORDER; MOTOR DYSFUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR DOWN REGULATION; REVIEW; SARCOSINEMIA; SCHIZOPHRENIA; STRESS; UPREGULATION;

AMINO ACID METABOLISM, INBORN ERRORS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SARCOSINE;

EID: 33750910038     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000236767.46526.1F     Document Type: Review

References (14)

1. Scott CR. Sarcosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: The McGraw-Hill Companies, Inc, 2001:2057-2063.
2. Gerritsen T, Waisman HA. Hypersarcosinemia: an inborn error of metabolism. N Engl J Med 1966;275(2):66-69.
3. Levy HL, Coulombe JT, Benjamin R. Massachusetts metabolic disorders screening program: III. sarcosinemia. Pediatrics 1984;74:509-513.
4. Gerritsen T. Sarcosine dehydrogenase deficiency, the enzyme defect in hypersarcosinemia. Helv Paediatr Acta 1972;27:33-37.
5. Scott CR, Clark SH, Teng CC, et al. Clinical and cellular studies of sarcosinemia. J Pediatr 1970;77:805-811.
6. Lane H-Y, Chang Y-C, Liu Y-C, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005;62(11):1196-1204.
7. Long KD, Mastropaolo J, Rosse RB, et al. Modulatory effects of D-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain. Brain Res Bull 2006;69(6):626-630.
8. Ascher P, Johnson JW. The NMDA receptor, its channel, and its modulation by glycine. In: Collingridge GL, Watkins JC, eds. The NMDA Receptor, 2nd ed. Oxford, UK: Oxford University Press, 1994:177-205.
9. Herdon HJ, Godfrey FM, Brown AM, et al. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 2001;41:88-96.
10. Deutsch SI, Mastropaolo J, Schwartz BL, et al. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989;12(1):1-13.
11. Deutsch SI, Long K, Rosse RB, et al. Animal models of psychosis. In: Fisch GS, Flint J, eds. Contemporary Clinical Neuroscience: Transgenic and Knockout Models of Neuropsychiatric Disorders. Totowa, NJ: Human Press Inc, 2006:193-220.
12. Deutsch SI, Rosse RB, Paul SM, et al. Inbred mouse strains differ in sensitivity to "popping" behavior elicited by MK-801. Pharmacol Biochem Behav 1997;57:315-317.
13. Deutsch SI, Mastropaolo J, Powell DG, et al. Inbred mouse strains differ in their sensitivity to an antiseizure effect of MK-801. Clin Neuropharmacol 1998;21(4):255-257.
14. Long KD, Mastropaolo J, Rosse RB, et al. Exogenously administered D-serine failed to potentiate the ability of MK-801 to antagonize electrically precipitated seizures in nonhandled control and stressed mice. Eur Neuropsychopharmacol In press.